2000 Participants Needed

Observational Study for Slipped Capital Femoral Epiphysis

(SLIP Trial)

AL
KM
Overseen ByKishore Mulpuri, FRCSC
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: University of British Columbia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to identify the best ways to treat Slipped Capital Femoral Epiphysis (SCFE), a hip condition common in teens. Researchers seek to determine which surgical treatments are most effective and have fewer long-term complications, such as avascular necrosis (bone death due to lack of blood flow) or joint issues. The trial will observe patients who are newly diagnosed, those treated at participating centers, and those treated elsewhere but continuing care at a participating center. This trial suits anyone under 18 diagnosed with SCFE who plans to receive follow-up care at one of the centers involved in the study. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the chance to contribute to a potentially groundbreaking treatment.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to gather comprehensive data on patients with Slipped Capital Femoral Epiphysis (SCFE) through a unique observational approach. Unlike typical treatment studies focused on testing new medications or surgical techniques, this registry tracks patients from diagnosis and through various treatment experiences, whether at the initial or outside centers. By following patients over time, the trial seeks to better understand the long-term outcomes of different treatment paths, potentially improving future care strategies for SCFE. This approach could reveal patterns and insights that current treatment studies might miss, leading to more personalized and effective treatment plans.

Who Is on the Research Team?

KM

Kishore Mulpuri, FRCSC

Principal Investigator

Principal Investigator

Are You a Good Fit for This Trial?

Inclusion Criteria

Confirmed diagnosis of SCFE
Intend to receiving follow-up at participating centre
Adequate diagnostic information and radiographic imaging (for patients previously treated for SCFE)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Registry Enrollment

Participants are enrolled into the international prospective registry for SCFE

Ongoing

Treatment

Participants receive surgical treatment options such as in-situ pinning or the Modified Dunn procedure

Varies based on treatment

Follow-up

Participants are monitored for clinical, functional, and radiographic outcomes

Long-term

What Are the Treatments Tested in This Trial?

Interventions

  • Observational

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Group I: Arm III: Prior treatment at outside centreExperimental Treatment1 Intervention
Group II: Arm II: Prior treatment at centreExperimental Treatment1 Intervention
Group III: Arm I: Prospective from diagnosisExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of British Columbia

Lead Sponsor

Trials
1,506
Recruited
2,528,000+